Payment overview · 2025
General Payments
$521.75
29 reported records · 6 companies
Healthcare provider profile · identity verified
Shilpi Singh, MD, MPH
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · JAMESBURG, NJ · NPI 1871970160
Verified facts
What the public records show
CMS Open Payments records show Shilpi Singh, MD, MPH received $521.75 in general payments during 2025 across 29 reported records.
Amneal Pharmaceuticals LLC accounted for 46.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Unithroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Synthroid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UNITHROID as an associated drug or biological on 7282 records involving 3230 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Unithroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 455 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $241.54 | 46.3% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $146.90 | 28.2% | 14 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$66.28 | 12.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $38.74 | 7.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.24 | 2.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.05 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $521.75 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $241.54 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $146.90 | 14 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $129.91 | 12 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $66.28 | 1 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $38.74 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 455 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 56 | exact normalized | Medicare Part D |
| UNITHROID unithroid |
2025 | Unithroid | 2024 | 50 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
188 | 52 |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | UNITHROID open payments reported associated product |
CMS Open Payments — General Payments 7282 supporting records · 3230 recipient NPIs · example record 1220525525 |
Unithroid · 2024 Exact normalized brand match · 1 Part D row |
50 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
455 | 109 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
56 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 735 | 208 |
| Ozempic | Semaglutide | 455 | 109 |
| Metformin Hcl | Metformin Hcl | 390 | 135 |
| Atorvastatin Calcium | Atorvastatin Calcium | 239 | 71 |
| Repaglinide | Repaglinide | 238 | 81 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 232 | 95 |
| Metformin Hcl Er | Metformin Hcl | 205 | 68 |
| Glimepiride | Glimepiride | 204 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 194 | 63 |
| Synthroid | Levothyroxine Sodium | 188 | 52 |
| Mounjaro | Tirzepatide | 173 | 40 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 169 | 59 |
| Jardiance | Empagliflozin | 163 | 45 |
| Glipizide | Glipizide | 154 | 54 |
| Trulicity | Dulaglutide | 131 | 33 |
| Humalog Kwikpen U-100 | Insulin Lispro | 115 | 40 |
| Farxiga | Dapagliflozin Propanediol | 113 | 30 |
| Losartan Potassium | Losartan Potassium | 101 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 93 | 29 |
| Lisinopril | Lisinopril | 87 | 25 |
| Novolog Flexpen | Insulin Aspart | 82 | 31 |
| Amlodipine Besylate | Amlodipine Besylate | 74 | 22 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 70 | 20 |
| Tresiba Flextouch U-200 | Insulin Degludec | 68 | 26 |
| Methimazole | Methimazole | 66 | 27 |
| Gabapentin | Gabapentin | 64 | 23 |
| Simvastatin | Simvastatin | 63 | 16 |
| Ezetimibe | Ezetimibe | 57 | 22 |
| Rybelsus | Semaglutide | 56 | 22 |
| Alendronate Sodium | Alendronate Sodium | 54 | 22 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 50 | 22 |
| Unithroid | Levothyroxine Sodium | 50 | 17 |
| Liothyronine Sodium | Liothyronine Sodium | 47 | 14 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 45 | 12 |
| Hydrocortisone | Hydrocortisone | 44 | 14 |
| Januvia | Sitagliptin Phosphate | 44 | 14 |
| Humalog | Insulin Lispro | 43 | 14 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 14 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 40 | 12 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 19 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 36 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 36 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 35 | 11 |
| Spironolactone | Spironolactone | 33 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 32 | 13 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 30 | 13 |
| Ondansetron Odt | Ondansetron | 28 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 25 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 25 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 24 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 23 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Novolog | Insulin Aspart | 21 | suppressed |
| Testosterone | Testosterone | 21 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 20 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 19 | 11 |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Cabergoline | Cabergoline | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Levoxyl | Levothyroxine Sodium | 13 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Teriparatide | Teriparatide | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Omeprazole | Omeprazole | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $521.75 · 29 records | Amneal Pharmaceuticals LLC | FREESTYLE LIBRE 3, KRYSTEXXA, MINIMED 780G, Ozempic, RINVOQ, Rybelsus, UNITHROID | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error